Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Página do item simplificado
dc.creatorGao, Jianjun
dc.creatorTian, Zhenxue
dc.creatorYang, Xu
dc.date.accessioned2020-04-06T19:46:01Z
dc.date.available2020-04-06T19:46:01Z
dc.date.issued2020
dc.description.abstractThe coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.pt_BR
dc.identifier.citationGAO, J.; TIAN, Z.; YANG, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends, [S.l.], v. 14, n. 1, 2020.pt_BR
dc.identifier.urihttps://repositorio.ufla.br/handle/1/39851
dc.identifier.urihttps://www.jstage.jst.go.jp/article/bst/14/1/14_2020.01047/_articlept_BR
dc.languageen_USpt_BR
dc.rightsopenAccesspt_BR
dc.sourceBioScience Trendspt_BR
dc.subjectCOVID-19pt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subject2019-nCoVpt_BR
dc.subjectPneumoniapt_BR
dc.subjectChloroquinept_BR
dc.titleBreakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studiespt_BR
dc.typeArtigopt_BR

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
license.txt
Tamanho:
953 B
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)